Source: Clinical Medicine

Key words：recombinant human erythropoietin; chronic anemia; symptomatic treatment of chronic anemia belong anemia common in clinical practice, the incidence rate was lower than in patients with iron deficiency anemia, usually resulting in the pathogenesis of a variety of factors of anemia At present, one of the main clinical reason to think of various inflammatory cytokines produced erythropoietin deficiency leads to hormone secretion, while the bone marrow response to erythropoietin decreased ability [11. 200 cases of chronic anemia in patients with epileptic group therapy, discuss the clinical efficacy of recombinant human erythropoietin treatment of chronic anemia.

1 Materials and Methods

1.1 General information: Choose from December 2012 to June 2013 200 cases of anemia in patients met the diagnostic criteria for chronic disease, divided into two groups according to treatment. Treated 100 cases of subcutaneous erythropoietin (rHuEPO), 30 males and 70 females, aged 32.5 -74.5 years; chronic diseases: rheumatoid arthritis 32 cases, 35 cases of systemic lupus erythematosus, systemic sclerosis 12 cases , 5 cases of chronic obstructive pulmonary disease, uremia nine cases, two cases of ulcerative colitis, two cases of lung abscess, diabetic patients with deep fungal infection in three cases. A control group of 100 usual routine primary disease treatment, 28 males and 72 females, aged 31.8- 73.7 years; chronic diseases: 31 cases of rheumatoid arthritis, systemic lupus erythematosus 33 cases, 13 cases of systemic sclerosis, chronic obstructive three cases of pulmonary disease, ulcerative colitis 3 cases, 12 cases of uremia, three cases of esophageal cancer surgery, diabetes mellitus and gangrene two cases. Two general information was no significant difference (P> 0.05), comparable Pi. 1.2 Treatment: primary disease treatment unchanged. For patients with iron deficiency of glucose injection, 3 times / week, 100 mg / times. While patients treated with subcutaneous injection rHuEPO, 2 times / week. 3000 U / second consecutive 8 weeks. The control group received conventional treatment of primary disease, including the use of antibiotics, immunosuppressants and other drugs symptomatic treatment of boils:

1.3 OUTCOME MEASURES: After treatment, the two groups were recorded test standard hematology and serum transferrin saturation and adverse reactions 1.4 Detection Methods: serum iron (SI) and even the use of automatic biochemical analyzer 7 right foot bag set, mainly used as Ferene colorimetry, kits used mainly for Shanghai Desai Diagnostics Ltd offers; for serum protein t SF, mainly by chemiluminescence even learn pan set, a kit used for the German Bater kit; serum transferrin by the pension (, STfR) were measured by ELISA.

1.5 Statistical Methods: SPSS 18.0 statistical software to analyze data, measurement data using the f test, P <0 05 for the difference was statistically significant.

2 Results

2.1 treatment: the treatment group of 100 cases in treatment for 3 weekend due to poor compliance and automatically exit four cases, due to the treatment of systemic sclerosis exacerbations quit one case 4 weeks, 8 weeks, more than 95 cases of treatment of heart palpitations, shortness of breath, fatigue, loss of appetite others have different degrees of improvement. Hematological treatment group, SI, SF, STfR other indicators improved compared with before treatment, the differences were statistically significant (P <0.05), in the control group, no improvement of clinical symptoms, the difference was not statistically significant (P <0.05). Table 1. Table 1 Man wins two disease anemia was observed before and after treatment compared between the two indexes. Two adverse reactions: early treatment group, four cases of drug slight headache, muscle pain light j teach two cases, were gradually improved with the treatment process.

3 Discussion

Erythropoietin is mainly meet unexpectedly secreted by the body's kidneys ball of cells a single chain glycoprotein, through continuous tests confirmed that recombinant human erythropoietin treatment is most successful technology currently used for recombinant DNA. The body of erythropoietin is a major regulator of erythropoiesis factor 2. Of red blood cells in bone marrow growth, differentiation and maturation can promote its mechanism of red blood cells by the bone marrow recipient with surface bonded to each other leaving the original body erythrocyte proliferation, differentiation and maturation. Erythropoietin also enables the expression of immature red blood cells in the bone marrow TfRI increased, thereby increasing the ability of cells in iron intake, increased red blood cell hemoglobin synthesis, reduced serum transferrin saturation '3: current clinical anemia of chronic disease pathogenesis is still unclear, this study of 200 patients selected group study found that patients through treatment after treatment, clinical symptoms, fatigue, palpitations, shortness of breath and other significant improvement, while various blood indicators compared to the different degrees of improvement appear before treatment, Compared to the control group of patients before treatment without any improvement. So for chronic anemia in patients with recombinant human erythropoietin treatment, significant clinical effect, safe and reliable, worthy of clinical application.